32
Participants
Start Date
September 30, 2019
Primary Completion Date
January 18, 2023
Study Completion Date
January 18, 2023
elapegademase-lvlr
Revcovi is administered intramuscularly (i.m.). Weekly dosage is calculated in mg/kg of body weight, and can be adjusted over the course of the trial based on ADA activity and dAXP concentration as well as on clinical assessment by the treating physician.
UBMD Pediatrics Outpatient Center, Buffalo
UPMC Children's Hospital of Pittsburgh, Pittsburgh
Penn State Children's Hospital, Hershey
Children's National, Washington D.C.
Duke University Hospital, Durham
University of South Florida Allergy Immunology Clinic, St. Petersburg
Le Bonheur Children's Hospital, Memphis
Children's Minnesota, Minneapolis
St. Louis Children's Hospital - Washington University School of Medicine, St Louis
Childrens Hospital of New Orleans, New Orleans
Allergy & Asthma Medical Group and Research Center, A P.C., San Diego
UCSF - University of California, San Francisco
Seattle Children's, Seattle
University of California Los Angeles, Los Angeles
Chiesi Farmaceutici S.p.A.
INDUSTRY